These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 19616557

  • 1. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution.
    Watabe T, Terakawa Y, Watanabe K, Ohno H, Nakano H, Nakatsu T, Kato H, Izumi K, Kodama E, Matsuoka M, Kitaura K, Oishi S, Fujii N.
    J Mol Biol; 2009 Sep 25; 392(3):657-65. PubMed ID: 19616557
    [Abstract] [Full Text] [Related]

  • 2. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M.
    Biochemistry; 2007 Apr 10; 46(14):4360-9. PubMed ID: 17371053
    [Abstract] [Full Text] [Related]

  • 3. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K, Nakamura S, Nakano H, Shimura K, Sakagami Y, Oishi S, Uchiyama S, Ohkubo T, Kobayashi Y, Fujii N, Matsuoka M, Kodama EN.
    Antiviral Res; 2010 Aug 10; 87(2):179-86. PubMed ID: 20438763
    [Abstract] [Full Text] [Related]

  • 4. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
    Soonthornsata B, Tian YS, Utachee P, Sapsutthipas S, Isarangkura-na-Ayuthaya P, Auwanit W, Takagi T, Ikuta K, Sawanpanyalert P, Kawashita N, Kameoka M.
    Virology; 2010 Sep 15; 405(1):157-64. PubMed ID: 20580393
    [Abstract] [Full Text] [Related]

  • 5. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M.
    J Virol; 2005 Jan 15; 79(2):764-70. PubMed ID: 15613304
    [Abstract] [Full Text] [Related]

  • 6. Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
    Ma X, Tan J, Su M, Li C, Zhang X, Wang C.
    PLoS One; 2014 Jan 15; 9(11):e111923. PubMed ID: 25393106
    [Abstract] [Full Text] [Related]

  • 7. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.
    Gallo SA, Clore GM, Louis JM, Bewley CA, Blumenthal R.
    Biochemistry; 2004 Jun 29; 43(25):8230-3. PubMed ID: 15209519
    [Abstract] [Full Text] [Related]

  • 8. Retrocyclin RC-101 overcomes cationic mutations on the heptad repeat 2 region of HIV-1 gp41.
    Fuhrman CA, Warren AD, Waring AJ, Dutz SM, Sharma S, Lehrer RI, Cole AL, Cole AM.
    FEBS J; 2007 Dec 29; 274(24):6477-87. PubMed ID: 18028423
    [Abstract] [Full Text] [Related]

  • 9. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R.
    J Mol Biol; 2004 Jun 25; 340(1):9-14. PubMed ID: 15184018
    [Abstract] [Full Text] [Related]

  • 10. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E, Hummer G, Bewley CA, Clore GM.
    J Med Chem; 2005 Apr 21; 48(8):3036-44. PubMed ID: 15828842
    [Abstract] [Full Text] [Related]

  • 11. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.
    Mo H, Konstantinidis AK, Stewart KD, Dekhtyar T, Ng T, Swift K, Matayoshi ED, Kati W, Kohlbrenner W, Molla A.
    Virology; 2004 Nov 24; 329(2):319-27. PubMed ID: 15518811
    [Abstract] [Full Text] [Related]

  • 12. Fatty acids can substitute the HIV fusion peptide in lipid merging and fusion: an analogy between viral and palmitoylated eukaryotic fusion proteins.
    Lev N, Shai Y.
    J Mol Biol; 2007 Nov 16; 374(1):220-30. PubMed ID: 17919659
    [Abstract] [Full Text] [Related]

  • 13. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.
    Desmezieres E, Gupta N, Vassell R, He Y, Peden K, Sirota L, Yang Z, Wingfield P, Weiss CD.
    J Virol; 2005 Apr 16; 79(8):4774-81. PubMed ID: 15795263
    [Abstract] [Full Text] [Related]

  • 14. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
    Zheng B, Wang K, Lu L, Yu F, Cheng M, Jiang S, Liu K, Cai L.
    AIDS; 2014 Jun 01; 28(9):1251-60. PubMed ID: 24625369
    [Abstract] [Full Text] [Related]

  • 15. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
    Korazim O, Sackett K, Shai Y.
    J Mol Biol; 2006 Dec 15; 364(5):1103-17. PubMed ID: 17045292
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.
    Izumi K, Kawaji K, Miyamoto F, Shimane K, Shimura K, Sakagami Y, Hattori T, Watanabe K, Oishi S, Fujii N, Matsuoka M, Kaku M, Sarafianos SG, Kodama EN.
    Int J Biochem Cell Biol; 2013 Apr 15; 45(4):908-15. PubMed ID: 23357451
    [Abstract] [Full Text] [Related]

  • 17. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
    Melikyan GB, Egelhofer M, von Laer D.
    J Virol; 2006 Apr 15; 80(7):3249-58. PubMed ID: 16537592
    [Abstract] [Full Text] [Related]

  • 18. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y, Chong H, Xiong S, Qiao Y, Qiu Z, He Y.
    J Virol; 2015 Dec 15; 89(24):12467-79. PubMed ID: 26446597
    [Abstract] [Full Text] [Related]

  • 19. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D, Ding X, Liu Z, Wu X, Zhu Y, Wei H, Chong H, Cui S, He Y.
    J Biol Chem; 2018 Aug 17; 293(33):12703-12718. PubMed ID: 29929981
    [Abstract] [Full Text] [Related]

  • 20. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.
    Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, Barbato G, Bianchi E, Miller MD, Pessi A, Carfí A.
    Nat Struct Mol Biol; 2006 Aug 17; 13(8):740-7. PubMed ID: 16862157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.